European Medicines Agency seeks more resources for future regulatory activities
This article was originally published in SRA
Executive Summary
Moves are under way to help ensure that the European Medicines Agency has sufficient resources for regulatory activities over the coming years, amid concerns that it might not be able to fund its new responsibilities in areas such as pharmacovigilance and counterfeit medicines.